Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LLY Eli Lilly and Company	$850.88 +0.9%	$736.97	$623.78 ▼ $937.00	$804.30B	0.47	4.10 million shs	506,869 shs
MRK Merck & Co., Inc.	$87.11 -0.6%	$83.06	$73.31 ▼ $111.58	$217.64B	0.37	14.99 million shs	1.11 million shs
NVO Novo Nordisk A/S	$59.97 +1.6%	$54.84	$45.05 ▼ $120.56	$267.66B	0.68	12.13 million shs	2.79 million shs
NVS Novartis	$132.92 +1.0%	$124.18	$96.06 ▼ $133.55	$280.48B	0.64	1.85 million shs	1.84 million shs
SWAV Shockwave Medical	$334.75	$332.85	$157.00 ▼ $334.90	$12.57B	0.88	968,088 shs	N/A

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LLY Eli Lilly and Company	-0.13%	+10.65%	+16.24%	+7.28%	-6.02%
MRK Merck & Co., Inc.	-1.35%	+4.37%	+3.60%	+4.65%	-19.29%
NVO Novo Nordisk A/S	-0.95%	+6.46%	+7.18%	-15.32%	-49.83%
NVS Novartis	-0.59%	+2.64%	+1.40%	+7.01%	+15.55%
SWAV Shockwave Medical	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LLY Eli Lilly and Company	$850.88 +0.9%	$736.97	$623.78 ▼ $937.00	$804.30B	0.47	4.10 million shs	506,869 shs
MRK Merck & Co., Inc.	$87.11 -0.6%	$83.06	$73.31 ▼ $111.58	$217.64B	0.37	14.99 million shs	1.11 million shs
NVO Novo Nordisk A/S	$59.97 +1.6%	$54.84	$45.05 ▼ $120.56	$267.66B	0.68	12.13 million shs	2.79 million shs
NVS Novartis	$132.92 +1.0%	$124.18	$96.06 ▼ $133.55	$280.48B	0.64	1.85 million shs	1.84 million shs
SWAV Shockwave Medical	$334.75	$332.85	$157.00 ▼ $334.90	$12.57B	0.88	968,088 shs	N/A

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LLY Eli Lilly and Company	-0.13%	+10.65%	+16.24%	+7.28%	-6.02%
MRK Merck & Co., Inc.	-1.35%	+4.37%	+3.60%	+4.65%	-19.29%
NVO Novo Nordisk A/S	-0.95%	+6.46%	+7.18%	-15.32%	-49.83%
NVS Novartis	-0.59%	+2.64%	+1.40%	+7.01%	+15.55%
SWAV Shockwave Medical	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LLY Eli Lilly and Company	2.64	Moderate Buy	$943.00	10.83% Upside
MRK Merck & Co., Inc.	2.29	Hold	$104.31	19.75% Upside
NVO Novo Nordisk A/S	2.50	Moderate Buy	$77.50	29.23% Upside
NVS Novartis	2.10	Hold	$120.33	-9.47% Downside
SWAV Shockwave Medical	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest NVS, LLY, MRK, NVO, and SWAV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/8/2025	LLY Eli Lilly and Company	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$875.00 ➝ $948.00
10/3/2025	LLY Eli Lilly and Company	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$1,028.00 ➝ $1,023.00
10/1/2025	NVO Novo Nordisk A/S	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$70.00
10/1/2025	LLY Eli Lilly and Company	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target		$700.00 ➝ $800.00
10/1/2025	NVO Novo Nordisk A/S	Hsbc Global Res Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
10/1/2025	NVO Novo Nordisk A/S	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$70.00
9/29/2025	NVO Novo Nordisk A/S	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Underweight	$59.00 ➝ $47.00
9/29/2025	NVO Novo Nordisk A/S	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
9/27/2025	LLY Eli Lilly and Company	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C+)
9/27/2025	MRK Merck & Co., Inc.	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C-)
9/27/2025	NVO Novo Nordisk A/S	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C-)

(Data available from 10/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LLY Eli Lilly and Company	$45.04B	17.88	$14.33 per share	59.37	$15.03 per share	56.61
MRK Merck & Co., Inc.	$64.17B	3.39	$9.29 per share	9.38	$18.33 per share	4.75
NVO Novo Nordisk A/S	$42.12B	6.36	$3.92 per share	15.29	$4.66 per share	12.87
NVS Novartis	$50.32B	5.58	$10.75 per share	12.36	$21.59 per share	6.16
SWAV Shockwave Medical	$787.97M	15.95	$4.31 per share	77.61	$20.02 per share	16.72

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LLY Eli Lilly and Company	$10.59B	$15.30	55.54	27.34	1.18	25.91%	92.72%	16.89%	10/30/2025 (Estimated)
MRK Merck & Co., Inc.	$17.12B	$6.49	13.43	8.80	0.91	25.79%	41.05%	16.55%	10/30/2025 (Estimated)
NVO Novo Nordisk A/S	$14.64B	$3.64	16.47	12.87	2.66	35.60%	78.64%	24.51%	11/5/2025 (Estimated)
NVS Novartis	$11.94B	$6.87	19.33	15.09	1.83	25.64%	41.08%	16.83%	10/28/2025 (Estimated)
SWAV Shockwave Medical	$147.28M	$4.28	78.21	54.34	2.43	20.75%	24.79%	11.95%	N/A

Latest NVS, LLY, MRK, NVO, and SWAV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2025	Q3 2025	NVO Novo Nordisk A/S	$0.90	N/A	N/A	N/A	$11.98 billion	N/A
10/30/2025	Q3 2025	LLY Eli Lilly and Company	$6.42	N/A	N/A	N/A	$16.09 billion	N/A
10/30/2025	Q3 2025	MRK Merck & Co., Inc.	$2.37	N/A	N/A	N/A	$17.00 billion	N/A
10/28/2025	Q3 2025	NVS Novartis	$2.28	N/A	N/A	N/A	$13.70 billion	N/A
8/7/2025	Q2 2025	LLY Eli Lilly and Company	$5.59	$6.31	+$0.72	$6.29	$14.40 billion	$15.56 billion
8/6/2025	Q2 2025	NVO Novo Nordisk A/S	$0.93	$0.97	+$0.04	$0.91	$77.51 billion	$11.69 billion
7/29/2025	Q2 2025	MRK Merck & Co., Inc.	$2.03	$2.13	+$0.10	$1.76	$15.92 billion	$15.81 billion
7/17/2025	Q2 2025	NVS Novartis	$2.38	$2.42	+$0.04	$2.06	$13.94 billion	$14.05 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
LLY Eli Lilly and Company	$6.00	0.71%	N/A	39.22%	11 Years
MRK Merck & Co., Inc.	$3.24	3.72%	N/A	49.92%	14 Years
NVO Novo Nordisk A/S	$0.82	1.37%	N/A	22.53%	N/A
NVS Novartis	$2.60	1.96%	N/A	37.85%	N/A
SWAV Shockwave Medical	N/A	N/A	N/A	N/A	N/A

Latest NVS, LLY, MRK, NVO, and SWAV Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/22/2025	MRK Merck & Co., Inc.	quarterly	$0.81	4%	9/15/2025	9/15/2025	10/7/2025
8/6/2025	NVO Novo Nordisk A/S	semi-annual	$0.4119	2.4%	8/18/2025	8/18/2025	8/26/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LLY Eli Lilly and Company	1.86	1.28	1.00
MRK Merck & Co., Inc.	0.69	1.42	1.17
NVO Novo Nordisk A/S	0.52	0.78	0.56
NVS Novartis	0.53	0.82	0.62
SWAV Shockwave Medical	0.97	13.81	12.61

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LLY Eli Lilly and Company	82.53%
MRK Merck & Co., Inc.	76.07%
NVO Novo Nordisk A/S	11.54%
NVS Novartis	13.12%
SWAV Shockwave Medical	95.35%

Insider Ownership

Company	Insider Ownership
LLY Eli Lilly and Company	0.14%
MRK Merck & Co., Inc.	0.09%
NVO Novo Nordisk A/S	0.07%
NVS Novartis	0.01%
SWAV Shockwave Medical	3.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LLY Eli Lilly and Company	47,000	946.46 million	945.13 million	Optionable
MRK Merck & Co., Inc.	75,000	2.50 billion	2.50 billion	Optionable
NVO Novo Nordisk A/S	77,349	4.47 billion	4.46 billion	Optionable
NVS Novartis	75,883	2.11 billion	2.11 billion	Optionable
SWAV Shockwave Medical	1,468	37.54 million	36.27 million	Optionable

NVS, LLY, MRK, NVO, and SWAV Headlines

Recent News About These Companies

Navigating Shockwave Medical: Applicant Admitted Prior Art, Standing, and Obviousness

August 4, 2025 | jdsupra.com

Shockwave Medical unveil Forward Intravascular Lithotripsy Platform in US

March 6, 2025 | medicaldialogues.inM

Shockwave Medical Launches Novel Forward Intravascular Lithotripsy Platform in U.S. to Transform Treatment of Difficult-to-Cross Calcified Lesions

March 4, 2025 | finance.yahoo.com

Shockwave Medical’s Javelin IVL catheter meets primary trial endpoints

November 5, 2024 | massdevice.com

Shockwave Medical concludes enrollment in all-female coronary IVL study

November 2, 2024 | medicaldialogues.inM

Shockwave completes enrollment in all-female cardiovascular trial

October 30, 2024 | bioworld.comB

Shockwave Medical completes enrollment in all-female IVL study

October 29, 2024 | massdevice.com

Micro-shockwave electronic therapy shows potential for safe non-invasive treatment of brain disorders

October 28, 2024 | medicalxpress.comM

Mayo Clinic Q&A: Shockwave therapy may help relieve foot problem

October 27, 2024 | postbulletin.comP

Johnson & Johnson completes $1.7B V-Wave acquisition

October 9, 2024 | massdevice.com

New shockwave therapy offers hope for chronic pain sufferers

September 25, 2024 | local12.comL

Shockwave E8: Extend Your Capabilities With the New Peripheral IVL Workhorse

September 24, 2024 | evtoday.comE

Shockwave E8 Peripheral IVL Catheter Launched

September 17, 2024 | evtoday.comE

Smiths Medical recalls airway tubes over defect linked to more than 10 injuries

September 17, 2024 | medtechdive.comM

J&J’s Shockwave adds enhanced catheter to U.S. IVL portfolio

September 17, 2024 | massdevice.com

J&J’s Shockwave strengths IVL grasp with new US catheter launch

September 17, 2024 | msn.com

New noninvasive technique provides effective treatment for urinary stones

September 12, 2024 | msn.com

Balancing Growth and Challenges: A Hold Rating for Johnson & Johnson’s Medtech Division Amidst China Headwinds

September 6, 2024 | markets.businessinsider.com

September 2024 edition: The Medtech Big 100, PFA catheters and Shockwave’s Reducer

August 30, 2024 | medicaldesignandoutsourcing.comM

Baird Q2 2024 Small/Mid Cap Growth Equity Fund Commentary

August 22, 2024 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NVS, LLY, MRK, NVO, and SWAV Company Descriptions

Eli Lilly and Company NYSE:LLY

$850.88 +7.25 (+0.86%)

As of 10:43 AM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Merck & Co., Inc. NYSE:MRK

$87.10 -0.51 (-0.58%)

As of 10:43 AM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Novo Nordisk A/S NYSE:NVO

$59.97 +0.95 (+1.61%)

As of 10:43 AM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Novartis NYSE:NVS

$132.92 +1.37 (+1.04%)

As of 10:43 AM Eastern

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Shockwave Medical NASDAQ:SWAV

Shockwave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels. It also provides product for the treatment of coronary artery disease, such as C2 IVL catheter and C2+IVL catheter that are two-emitter catheters for use in IVL system; and Reducer, a device to treat refractory angina. In addition, the company develops COSIRA-II trial; shockwave C2 Aero, a coronary IVL catheter; shockwave javelin coronary, a non-balloon-based catheter platform to treat of tight, difficult-to-cross coronary lesions; shockwave L6; shockwave E8 catheter, to target long peripheral artery lesions; shockwave javelin peripheral, a non-balloon-based catheter platform, to treat tight, difficult-to-cross peripheral lesions. Further, it offers shockwave carotid IVL, a purpose-built IVL System to treat calcified carotid artery lesions; and Shockwave Crescendo, a platform developed to treat calcified, stenotic heart valves. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NVS, LLY, MRK, NVO, and SWAV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NVS, LLY, MRK, NVO, and SWAV Earnings

Compare Dividends

Latest NVS, LLY, MRK, NVO, and SWAV Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NVS, LLY, MRK, NVO, and SWAV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NVS, LLY, MRK, NVO, and SWAV Company Descriptions

Eli Lilly and Company NYSE:LLY

Merck & Co., Inc. NYSE:MRK

Novo Nordisk A/S NYSE:NVO

Novartis NYSE:NVS

Shockwave Medical NASDAQ:SWAV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools